The significance of serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibody determination in patients with congestive heart failure

doi:10.3969/j.issn.1673-8640.2014.02.001

›› 2014, Vol. 29 ›› Issue (2): 97-99.DOI: 10.3969/j.issn.1673-8640.2014.02.001

The significance of serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibody determination in patients with congestive heart failure

LIU Chengeng¹, XIA Ming², WANG Jinling¹, LI Lei¹, WANG Peichang¹

1. Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; 2. Department of Clinical Laboratory, Central Hospital of Minhang District, Shanghai 201100, China

Received:2013-02-04 Online:2014-02-20 Published:2014-02-20

Abstract

Abstract: Objective To determine serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibodies, the level of antioxidants and cytokines in patients with congestive heart failure (CHF) by established methods, and to evaluate primarily the clinical significance. Methods The serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibodies, erythrocyte sedimentation rate(ESR), the levels of 5 kinds of cytokines [like interleukin 2 (IL-2)] and 5 kinds of antioxidants [like superoxide dismutase (SOD)] from 58 patients with CHF in recent 3 months to 1 year were determined.Results The level of serum anti-carbonic anhydrase Ⅱ auto-antibody in CHF patients was significantly higher than that in control group (P<0.05). The levels of SOD, glutathione peroxidase (GPx), catalase (CAT) and total antioxidant capacity (TAC) in CHF patients were significantly lower than those in control group (P<0.05), while methanedicarboxylic aldehyde (MDA) level was significantly higher than that in control group(P<0.05). There was no statistical significance on the levels of interleukin (IL-6), tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) between CHF patients and control group (P>0.05), while IL-2 and interleukin 17(IL-17) levels were significantly higher than those in control group (P<0.05). Conclusions There may be autoimmune phenomenon in CHF patients. IL-2, IL-17 and antioxidant capacity may be used as the markers for the diagnosis of anti-carbonic anhydrase Ⅱ auto-antibody.

Key words: Auto-antibody, Carbonic anhydrase Ⅱ, Carbonic anhydrase Ⅲ, Congestive heart failure

CLC Number:

R446.62

LIU Chengeng, XIA Ming, WANG Jinling, LI Lei, WANG Peichang. The significance of serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibody determination in patients with congestive heart failure[J]. , 2014, 29(2): 97-99.

References

[1] Martínez-Borra J, López-Larrea C. Autophagy and self-defense [J]. Adv Exp Med Biol, 2012, 738: 169-184.
[2] Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction [J]. Circ Res, 2012, 110(1): 145-158.
[3] 刘辰庚, 王培昌. 缺氧状态下雌二醇对H9c2细胞碳酸酐酶Ⅳ表达的影响 [J]. 医学研究杂志, 2012, 41(9): 86-88.
[4] Liu C, Wei Y, Wang J, et al. Carbonic anhydrases Ⅲ and Ⅳ autoantibodies in rheumatoid arthritis, sys-temic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure [J]. Clin Dev Immunol, 2012, 2012: 354594.
[5] Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications[J]. Future Med Chem, 2011, 3(9): 1165-1180.
[6] Hosoda H, Okawa-Takatsuji M, Shinmura W, et al. Potential for differential diagnosis of autoimmune pancreatitis and pancreatic cancer using carbonic anhydrase Ⅱ antibody [J]. Pancreas, 2008, 37(1): e1-e7.
[7] Sánchez-Castaón M, de las Heras-Castao G, López-Hoyos M. Autoimmune pancreatitis: an under-diagnosed autoimmune disease with clinical, imaging and serological features [J]. Autoimmun Rev, 2010, 9(4): 237-240.
[8] Biswas UK, Kumar A. Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal [J]. J Pak Med Assoc, 2012, 62(5): 417-421.
[9] Yamada H. Current perspectives on the role of IL-17 in autoimmune disease [J]. J Inflamm Res, 2010, 3: 33-44.
[10] 仲人前. 应提倡自身免疫性疾病实验室诊断研究的原创性和实用性 [J]. 检验医学, 2006, 21(2): 89-90.
[11] Li W, Wang W, Sun S, et al. Autoantibodies against the catalytic domain of BRAF are not specific serum markers for rheumatoid arthritis [J]. PLoS One, 2011, 6(12): e28975.
[12] Zimmerman UJ, Wang P, Zhang X, et al. Anti-oxidative response of carbonic anhydrase Ⅲ in skeletal muscle [J]. IUBMB Life, 2004, 56(6): 343-347.
[13] Soares SR, Martínez-Varea A, Hidalgo-Mora JJ, et al. Pharmacologic therapies in endometriosis: a syste-matic review [J]. Fertil Steril, 2012, 98(3): 529-555.
[14] Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics--an update [J]. Eur J Pharmacol, 2008, 579(1-3): 1-12.

The significance of serum anti-carbonic anhydrase Ⅱ and Ⅲ auto-antibody determination in patients with congestive heart failure

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

[1]	CHEN Yiqiong, ZHAO Di, LI Zhi.. The progress of anti-carbamylated protein antibody [J]. Laboratory Medicine, 2015, 30(8): 857-860.
[2]	WANG Chenggang;YU Feifei;FANG Haijun;CHEN Yanqin. The diagnosis value of the N-terminal pro-B-type natriuretic peptide for the patients with dyspnea in emergency department [J]. , 2010, 25(03): 219-223.